Share on LinkedInShare on LinkedIn

ARTICLE · 20 AUGUST 2026

Priority Patent Applications For Biotech And Chemistry Startups

Biotechnology and chemistry startups face a critical question when filing priority patent applications: how much experimental data is actually required? While the answer depends on the predictability of the technology, the European Patent Office's strict disclosure standards mean that insufficient technical support can invalidate priority claims entirely, leaving innovations vulnerable to competitor filings and prior art that emerges during the assumed protection period.

United KingdomIntellectual Property

ARTICLE SUMMARY

  • There is no universal requirement for experimental data before filing a priority application; it depends on the technology and what the application needs to achieve.
  • At the EPO, the priority application must disclose the invention directly and unambiguously and provide an enabling disclosure, rather than simply describing a hoped-for outcome.
  • Less data may be needed in predictable fields, while unpredictable areas such as therapeutics and complex biology may require more technical support to make the invention credible.
  • For startups, the priority application should be filed early but include enough technical rationale, data and detail to genuinely disclose the invention, as priority problems are often harder to fix later.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from